Leinco Technologies Inc. Acquires QED Biosciences, Leading Provider of Antibodies, Related Reagents, and Development Services
The strategic acquisition will enable Leinco to expand its portfolio of antibody capabilities used globally for research and diagnostics. St. Louis, MO, September 3, 2024 - Leinco Technologies (“Leinco”), a trusted source of high-quality [...]
Launch of chimeric anti-mouse PD1 and PD-L1 recombinant antibodies
Leinco Technologies Highlights Launch of the new mAbMods™ chimeric anti-mouse PD1 and PD-L1 recombinant antibodies for use in in vivo functional studies ST. LOUIS, April 17, 2023 –Leinco Technologies (“Leinco”) ( St. Louis, MO), a [...]
Antibodies Targeting an Array of Infectious Diseases: Leinco and VUMC Advance Research and Diagnostics
Strategic Collaboration: Leinco Technologies and Vanderbilt University Medical Center ST. LOUIS, October 19, 2021 –Leinco Technologies, Inc (Leinco), a leading contract development manufacturing organization (CDMO) and life science tools company, today announced an agreement with [...]
Development of novel COVID-19 diagnostic tools
Leinco Technologies, Inc. and La Jolla Institute for Immunology announce license agreement to develop novel COVID-19 diagnostic tools LA JOLLA, CA— La Jolla Institute for Immunology (LJI), one of the leading research organizations dedicated to [...]
Leinco receives CODEX® licensing rights
Akoya Biosciences, Inc. and Leinco Technologies, Inc. Announce Strategic Partnership for Customized CODEX Antibody Panel Design and Validation ST. LOUIS, April 22, 2020-- Leinco Technologies (St. Louis, MO) and Akoya Biosciences, (Menlo Park, CA) have [...]
Strategic Partnership: Leinco Technologies and Vanderbilt University Medical Center
Development of rapid, point of care, immunodiagnostic test for detection of the SARS-CoV-2 (COVID-19) ST. LOUIS, April 16, 2020-- Leinco Technologies, Inc., a premier developer and manufacturer of leading-edge recombinant proteins, antibodies, conjugates and provider [...]
